Novavax Inc. announced today that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in the European Union (EU) for adolescents aged 12 through 17.
https://www.pharmalive.com/wp-content/uploads/2022/07/Novavax_High_Res_Logo.jpg6091382PR Newswirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngPR Newswire2022-07-05 09:30:162022-07-05 10:34:05Novavax COVID-19 vaccine conditionally authorized in the EU for adolescents aged 12 through 17
